Protein Kinase Inhibitors: all 15,278 studies that test it

Page 43 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.

• A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02549937Phase 1/2Results posted
• Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple MyelomaTerminatedNCT02548962Phase 1/2Results posted
• Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.CompletedNCT02546674Phase 4Results posted
• Eurosarc Trial of Linsitinib in Advanced Ewing SarcomaCompletedNCT02546544Phase 2Results posted
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in METCompletedNCT02544633Phase 2Results posted
• Trial Using Gilotrif for Advanced Penile Squamous Cell CarcinomaTerminatedNCT02541903Phase 2Results posted
• Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on EverolimusTerminatedNCT02539459Phase 2Results posted
• A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT02537613Phase 1Results posted
• Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)CompletedNCT02537444Phase 2Results posted
• Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast CancerCompletedNCT02536742Phase 2Results posted
• Dose Optimization Study of Idelalisib in Follicular LymphomaTerminatedNCT02536300Phase 3Results posted
• SLM + Axitinib for Clear Cell RCCCompletedNCT02535533Phase 1/2Results posted
• Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerCompletedNCT02535338Phase 1/2Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic LeukemiaStatus unknownNCT02530619Not applicableResults posted
• Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid LeukemiaCompletedNCT02530476Phase 1/2Results posted
• Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB PreservedCompletedNCT02530320Phase 2Results posted
• Phase I, Study in Chinese NSCLC PatientsCompletedNCT02529995Phase 1Results posted
• LEE001 and Chemoembolization In Patients With Advanced Hepatocellular CarcinomaTerminatedNCT02524119Phase 2Results posted
• A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute ExacerbationCompletedNCT02522299Phase 2Results posted
• Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver FunctionCompletedNCT02521376Phase 1Results posted
• Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerTerminatedNCT02521051Phase 1/2Results posted
• Alvocidib Biomarker-driven Phase 2 AML StudyTerminatedNCT02520011Phase 2Results posted
• Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With RadiotherapyCompletedNCT02516813Phase 1Results posted
• Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedNCT02515630Phase 2Results posted
• MLN0128 in Recurrent/Metastatic Merkel Cell CarcinomaCompletedNCT02514824Phase 1/2Results posted
• Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan ChemotherapyCompletedNCT02514447Phase 1/2Results posted
• Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or OlderCompletedNCT02514174Phase 4Results posted
• A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLLActive, not recruitingNCT02514083Phase 2Results posted
• Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung AdenocarcinomaTerminatedNCT02513667Phase 2Results posted
• AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung CancerCompletedNCT02513563Phase 2Results posted
• PALbociclib CoLlaborative Adjuvant StudyActive, not recruitingNCT02513394Phase 3Results posted
• Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula OutcomesCompletedNCT02513303Phase 3Results posted
• Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer PatientsTerminatedNCT02511184Phase 1Results posted
• AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.Active, not recruitingNCT02511106Phase 3Results posted
• MEK and MET Inhibition in Colorectal CancerCompletedNCT02510001Phase 1Results posted
• Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic FunctionCompletedNCT02509624Phase 1Results posted
• (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid TumorsCompletedNCT02508532Phase 1Results posted
• A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02507375Phase 1Results posted
• Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal CancerTerminatedNCT02504892Phase 2Results posted
• Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingNCT02502266Phase 2/3Results posted
• Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDACCompletedNCT02501902Phase 1Results posted
• A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT02501096Phase 1/2Results posted
• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)CompletedNCT02499770Phase 1/2Results posted
• Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast CancerCompletedNCT02499146Phase 1Results posted
• Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck CancerCompletedNCT02499120Phase 2Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation PneumonitisCompletedNCT02496585Phase 2Results posted
• A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02495233Phase 1/2Results posted
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaTerminatedNCT02495103Phase 1/2Results posted
• LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPCCompletedNCT02494921Phase 1/2Results posted
• A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComaCompletedNCT02494570Phase 2Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)CompletedNCT02493751Phase 1Results posted
• A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291CompletedNCT02491944Phase 1Results posted
• A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSCompletedNCT02488408Phase 1/2Results posted
• Examining the Impact of Sirolimus on Ketamine's Antidepressant EffectsCompletedNCT02487485Phase 2Results posted
• Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersCompletedNCT02487095Phase 1/2Results posted
• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02484430Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without FoodCompletedNCT02482935Phase 1Results posted
• Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid TumorsTerminatedNCT02478320Phase 2Results posted
• Trial of Ponatinib in Patients With Bevacizumab-Refractory GlioblastomaCompletedNCT02478164Phase 2Results posted
• Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT02477696Phase 3Results posted
• Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLActive, not recruitingNCT02475681Phase 3Results posted
• Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected AdultsCompletedNCT02475655Phase 2Results posted
• Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLCCompletedNCT02474355Phase 3Results posted
• Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02469415Phase 2Results posted
• Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02468557Phase 1Results posted
• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedNCT02467270Phase 2Results posted
• Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3CompletedNCT02466516Phase 2Results posted
• Regorafenib in Metastatic Colorectal CancerCompletedNCT02466009Phase 2Results posted
• Ceritinib Rare Indications Study in ALK+ TumorsTerminatedNCT02465528Phase 2Results posted
• Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)CompletedNCT02459119Phase 2Results posted
• Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerTerminatedNCT02457910Phase 1/2Results posted
• A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT02457793Phase 1Results posted
• Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesTerminatedNCT02457598Phase 1Results posted
• Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell MalignanciesCompletedNCT02457559Phase 1Results posted
• Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot InitiativeCompletedNCT02456857Phase 2Results posted
• Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive TumoursCompletedNCT02454933Phase 3Results posted
• Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT02454478Phase 1Results posted
• Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation TherapyTerminatedNCT02452463Phase 2Results posted
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsTerminatedNCT02452424Phase 1/2Results posted
• A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDCompletedNCT02451696Phase 2Results posted
• LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.CompletedNCT02450903Phase 2Results posted
• Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR MutationsCompletedNCT02450591Not applicableResults posted
• A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung CancerCompletedNCT02450539Phase 2Results posted
• A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast CancerCompletedNCT02448771Phase 1/2Results posted
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02446600Phase 3Results posted
• Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT02446236Phase 1Results posted
• A Study of LY3023414 and Necitumumab in Squamous Lung CancerTerminatedNCT02443337Phase 2Results posted
• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT02443077Phase 3Results posted
• Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia PacificCompletedNCT02442349Phase 2Results posted
• A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerCompletedNCT02441946Phase 2Results posted
• Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)CompletedNCT02440789Phase 1/2Results posted
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedNCT02440685Phase 1/2Results posted
• Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström MacroglobulinemiaTerminatedNCT02439138Phase 2Results posted
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.CompletedNCT02437318Phase 3Results posted
• Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833CompletedNCT02437227Phase 1Results posted
• Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)CompletedNCT02436668Phase 3Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseTerminatedNCT02436135Phase 1Results posted
• Study of Efficacy of CDZ173 in Patients With APDS/PASLICompletedNCT02435173Phase 2/3Results posted

← Protein Kinase Inhibitors overview